High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma.

Pia Roering¹, Lilla Csellar², Sami Blom³, Iona Raineva⁴, Kia Colangelo⁴, Satu Hänninen⁵, Anna Ray Laury⁶, Vanina D Heuser⁷, Olli Carpén⁶

¹Department of Pathology, Institute of Biomedicine and FICAN West Cancer Centre, Faculty of Medicine, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine (TuDMM), Faculty of Medicine, University of Turku, Turku, Finland; Department of Pathology, Lapland Central Hospital, Rovaniemi, Finland.

²Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland. Electronic address: lilla.csellar@helsinki.fi.

³Aiforia Technologies Plc, Helsinki, Finland.

⁴Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.

⁵Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

⁶Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.

⁷Department of Pathology, Institute of Biomedicine and FICAN West Cancer Centre, Faculty of Medicine, University of Turku, Turku, Finland.

PubMed DOI

Abstract

OBJECTIVE: Tubo-ovarian high-grade serous carcinoma (HGSC) has a poor prognosis due to limited treatment options, therapy resistance, and high recurrence rates. One proposed mechanism underlying treatment failure is the survival of cancer stem cells (CSCs) following chemotherapy. In previous in vitro studies, we identified ALDH1A1, SOX2, MYC, and BMI1 as putative CSC markers, with increased expres…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.